Novartis AG is partnering with Lindy Biosciences to make biologics normally available only as intravenous injections suitable for subcutaneous self-administration, which the companies said would improve outcomes as well as compliance among patients. For Novartis, it shows the company is interested in making its biologics – especially monoclonal antibodies – easier for patients to use, but is also taking a different tack from other pharma companies that have created subcutaneous versions of their products.
Honey, I Shrunk The Drugs: Novartis, Lindy Partner On Biologics Delivery
Novartis is paying Lindy potentially more than $900m to use its technology for making intravenous biologics available for subcutaneous injection using autoinjectors.
More from Deals
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.